Chemomab Therapeutics Ltd.

NasdaqCM:CMMB

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Israel

Market Cap

USD 23.00 M

Share Price

USD 1.20

Avg Daily Volume

130,882

Change (1 day)

0.00%

Change (1 year)

17.65%

Change (YTD)

-33.70%

Chemomab Therapeutics Ltd. Free Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2024

Chemomab Therapeutics Ltd. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending December 31, 2024. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Chemomab Therapeutics Ltd. Free Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2023 was USD -23.71 M, a 16.00% change year over year.
Chemomab Therapeutics Ltd. Free Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2022 was USD -20.44 M, a 62.04% change year over year.
Chemomab Therapeutics Ltd. Free Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2021 was USD -12.61 M, a 138.89% change year over year.
Chemomab Therapeutics Ltd. Free Cash Flow for the Trailing 12 Months (TTM) ending December 31, 2020 was USD -5.28 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqCM: CMMB

Chemomab Therapeutics Ltd.

CEO	Dr. Adi Mor George Ph.D.
IPO Date	Feb. 12, 2019
Location	Israel
Headquarters	Building 7
Employees	20
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.